These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

531 related articles for article (PubMed ID: 34743554)

  • 1. Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial.
    Berg DD; Docherty KF; Sattar N; Jarolim P; Welsh P; Jhund PS; Anand IS; Chopra V; de Boer RA; Kosiborod MN; Nicolau JC; O'Meara E; Schou M; Hammarstedt A; Langkilde AM; Lindholm D; Sjöstrand M; McMurray JJV; Sabatine MS; Morrow DA
    Circulation; 2022 Jan; 145(3):158-169. PubMed ID: 34743554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial.
    Butt JH; Adamson C; Docherty KF; de Boer RA; Petrie MC; Inzucchi SE; Kosiborod MN; Maria Langkilde A; Lindholm D; Martinez FA; Bengtsson O; Schou M; O'Meara E; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Jhund PS; McMurray JJV; Køber L
    Circ Heart Fail; 2021 Dec; 14(12):e008837. PubMed ID: 34802253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.
    Nassif ME; Windsor SL; Tang F; Khariton Y; Husain M; Inzucchi SE; McGuire DK; Pitt B; Scirica BM; Austin B; Drazner MH; Fong MW; Givertz MM; Gordon RA; Jermyn R; Katz SD; Lamba S; Lanfear DE; LaRue SJ; Lindenfeld J; Malone M; Margulies K; Mentz RJ; Mutharasan RK; Pursley M; Umpierrez G; Kosiborod M
    Circulation; 2019 Oct; 140(18):1463-1476. PubMed ID: 31524498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction.
    Berg DD; Jhund PS; Docherty KF; Murphy SA; Verma S; Inzucchi SE; Køber L; Kosiborod MN; Langkilde AM; Martinez FA; Bengtsson O; Ponikowski P; Sjöstrand M; Solomon SD; McMurray JJV; Sabatine MS
    JAMA Cardiol; 2021 May; 6(5):499-507. PubMed ID: 33595593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial.
    Kosiborod MN; Jhund PS; Docherty KF; Diez M; Petrie MC; Verma S; Nicolau JC; Merkely B; Kitakaze M; DeMets DL; Inzucchi SE; Køber L; Martinez FA; Ponikowski P; Sabatine MS; Solomon SD; Bengtsson O; Lindholm D; Niklasson A; Sjöstrand M; Langkilde AM; McMurray JJV
    Circulation; 2020 Jan; 141(2):90-99. PubMed ID: 31736335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF.
    Docherty KF; Jhund PS; Anand I; Bengtsson O; Böhm M; de Boer RA; DeMets DL; Desai AS; Drozdz J; Howlett J; Inzucchi SE; Johanson P; Katova T; Køber L; Kosiborod MN; Langkilde AM; Lindholm D; Martinez FA; Merkely B; Nicolau JC; O'Meara E; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Tereshchenko S; Verma S; McMurray JJV
    Circulation; 2020 Oct; 142(17):1623-1632. PubMed ID: 32883108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF.
    Martinez FA; Serenelli M; Nicolau JC; Petrie MC; Chiang CE; Tereshchenko S; Solomon SD; Inzucchi SE; Køber L; Kosiborod MN; Ponikowski P; Sabatine MS; DeMets DL; Dutkiewicz-Piasecka M; Bengtsson O; Sjöstrand M; Langkilde AM; Jhund PS; McMurray JJV
    Circulation; 2020 Jan; 141(2):100-111. PubMed ID: 31736328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF.
    Yeoh SE; Docherty KF; Campbell RT; Jhund PS; Hammarstedt A; Heerspink HJL; Jarolim P; Køber L; Kosiborod MN; Martinez FA; Ponikowski P; Solomon SD; Sjöstrand M; Bengtsson O; Greasley PJ; Sattar N; Welsh P; Sabatine MS; Morrow DA; McMurray JJV
    Circulation; 2023 May; 147(22):1670-1683. PubMed ID: 37039015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF.
    Jhund PS; Solomon SD; Docherty KF; Heerspink HJL; Anand IS; Böhm M; Chopra V; de Boer RA; Desai AS; Ge J; Kitakaze M; Merkley B; O'Meara E; Shou M; Tereshchenko S; Verma S; Vinh PN; Inzucchi SE; Køber L; Kosiborod MN; Martinez FA; Ponikowski P; Sabatine MS; Bengtsson O; Langkilde AM; Sjöstrand M; McMurray JJV
    Circulation; 2021 Jan; 143(4):298-309. PubMed ID: 33040613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF.
    Jackson AM; Dewan P; Anand IS; Bělohlávek J; Bengtsson O; de Boer RA; Böhm M; Boulton DW; Chopra VK; DeMets DL; Docherty KF; Dukát A; Greasley PJ; Howlett JG; Inzucchi SE; Katova T; Køber L; Kosiborod MN; Langkilde AM; Lindholm D; Ljungman CEA; Martinez FA; O'Meara E; Sabatine MS; Sjöstrand M; Solomon SD; Tereshchenko S; Verma S; Jhund PS; McMurray JJV
    Circulation; 2020 Sep; 142(11):1040-1054. PubMed ID: 32673497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials.
    McMurray JJV; Docherty KF; de Boer RA; Hammarstedt A; Kitzman DW; Kosiborod MN; Maria Langkilde A; Reicher B; Senni M; Shah SJ; Wilderäng U; Verma S; Solomon SD
    Circulation; 2024 Mar; 149(11):825-838. PubMed ID: 38059368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial.
    Docherty KF; Jhund PS; Claggett B; Ferreira JP; Bengtsson O; Inzucchi SE; Køber L; Kosiborod MN; Langkilde AM; Martinez FA; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; McMurray JJV;
    JAMA Cardiol; 2021 Nov; 6(11):1298-1305. PubMed ID: 34319398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Carbohydrate Antigen 125 on the Response to Dapagliflozin in Patients With Heart Failure.
    Docherty KF; McDowell K; Welsh P; Osmanska J; Anand I; de Boer RA; Køber L; Kosiborod MN; Martinez FA; O'Meara E; Ponikowski P; Schou M; Berg DD; Sabatine MS; Morrow DA; Jarolim P; Hammarstedt A; Sjöstrand M; Langkilde AM; Solomon SD; Sattar N; Jhund PS; McMurray JJV
    J Am Coll Cardiol; 2023 Jul; 82(2):142-157. PubMed ID: 37407113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial.
    Butt JH; Docherty KF; Petrie MC; Schou M; Kosiborod MN; O'Meara E; Katova T; Ljungman CEA; Diez M; Ogunniyi MO; Langkilde AM; Sjöstrand M; Lindholm D; Bengtsson O; Martinez FA; Ponikowski P; Sabatine MS; Solomon SD; Jhund PS; McMurray JJV; Køber L
    JAMA Cardiol; 2021 Jun; 6(6):678-689. PubMed ID: 33787831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes.
    Petrie MC; Verma S; Docherty KF; Inzucchi SE; Anand I; Belohlávek J; Böhm M; Chiang CE; Chopra VK; de Boer RA; Desai AS; Diez M; Drozdz J; Dukát A; Ge J; Howlett J; Katova T; Kitakaze M; Ljungman CEA; Merkely B; Nicolau JC; O'Meara E; Vinh PN; Schou M; Tereshchenko S; Køber L; Kosiborod MN; Langkilde AM; Martinez FA; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Johanson P; Greasley PJ; Boulton D; Bengtsson O; Jhund PS; McMurray JJV
    JAMA; 2020 Apr; 323(14):1353-1368. PubMed ID: 32219386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER.
    Kondo T; Butt JH; Curtain JP; Jhund PS; Docherty KF; Claggett BL; Vaduganathan M; Bachus E; Hernandez AF; Lam CSP; Inzucchi SE; Martinez FA; de Boer RA; Kosiborod MN; Desai AS; Køber L; Ponikowski P; Sabatine MS; Solomon SD; McMurray JJV
    Circ Heart Fail; 2023 Dec; 16(12):e010898. PubMed ID: 37886880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction: Findings From DAPA-HF.
    Adamson C; Welsh P; Docherty KF; de Boer RA; Diez M; Drożdż J; Dukát A; Inzucchi SE; Køber L; Kosiborod MN; Ljungman CEA; Martinez FA; Ponikowski P; Sabatine MS; Morrow DA; Lindholm D; Hammarstedt A; Boulton DW; Greasley PJ; Langkilde AM; Solomon SD; Sattar N; McMurray JJV; Jhund PS
    JACC Heart Fail; 2023 Mar; 11(3):291-304. PubMed ID: 36592046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
    Kato ET; Silverman MG; Mosenzon O; Zelniker TA; Cahn A; Furtado RHM; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Bonaca MP; Ruff CT; Desai AS; Goto S; Johansson PA; Gause-Nilsson I; Johanson P; Langkilde AM; Raz I; Sabatine MS; Wiviott SD
    Circulation; 2019 May; 139(22):2528-2536. PubMed ID: 30882238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
    McMurray JJV; Solomon SD; Inzucchi SE; Køber L; Kosiborod MN; Martinez FA; Ponikowski P; Sabatine MS; Anand IS; Bělohlávek J; Böhm M; Chiang CE; Chopra VK; de Boer RA; Desai AS; Diez M; Drozdz J; Dukát A; Ge J; Howlett JG; Katova T; Kitakaze M; Ljungman CEA; Merkely B; Nicolau JC; O'Meara E; Petrie MC; Vinh PN; Schou M; Tereshchenko S; Verma S; Held C; DeMets DL; Docherty KF; Jhund PS; Bengtsson O; Sjöstrand M; Langkilde AM;
    N Engl J Med; 2019 Nov; 381(21):1995-2008. PubMed ID: 31535829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of sodium-glucose co-transporter 2 inhibition according to left ventricular ejection fraction in DAPA-HF.
    Dewan P; Solomon SD; Jhund PS; Inzucchi SE; Køber L; Kosiborod MN; Martinez FA; Ponikowski P; DeMets DL; Sabatine MS; Bengtsson O; Sjöstrand M; Langkilde AM; Anand IS; Bělohlávek J; Chopra VK; Dukát A; Kitakaze M; Merkely B; O'Meara E; Schou M; Vinh PN; McMurray JJV;
    Eur J Heart Fail; 2020 Jul; 22(7):1247-1258. PubMed ID: 32539224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.